<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303419</url>
  </required_header>
  <id_info>
    <org_study_id>DE-CEDM-001</org_study_id>
    <nct_id>NCT01303419</nct_id>
  </id_info>
  <brief_title>Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer</brief_title>
  <official_title>A Multicenter, Open-Label, Crossover Trial to Assess Non-Inferiority of Dual Energy Contrast-Enhanced Digital Mammography (DE-CEDM) Compared to Contrast-Enhanced Breast Magnetic Resonance Imaging (CE-BMRI) for Identifying a Change in Patient Management in Women With Newly Diagnosed Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GE Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Enrolled women will undergo a bilateral Contrast-Enhanced Breast Magnetic Resonance Imaging
      (CE-BMRI) as per usual clinical practice within 30 days of breast cancer diagnosis. Up to 8
      weeks after the CE-BMRI exam, subjects will undergo a Dual Energy Contrast Enhanced Digital
      Mammograph (DE-CEDM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled women will undergo a bilateral Contrast-Enhanced Breast Magnetic Resonance Imaging
      (CE-BMRI) as per usual clinical practice within 30 days of breast cancer diagnosis. Up to 8
      weeks after the CE-BMRI exam, subjects will undergo a Dual Energy Contrast Enhanced Digital
      Mammograph (DE-CEDM). Maximum lesion size was compared between the two imaging types. Subject
      data from both scans was planned to be included in a multi-reader evaluation; however, due to
      premature stop of the study, multi-reader data was not collected.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor determined there was sufficient material collected to answer the study questions.
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 30, 2012</completion_date>
  <primary_completion_date type="Actual">June 30, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completion of CE-BMRI and DE-CEDM</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>Subjects have completed both CE-BMRI and DE-CEDM scan types</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Maximum Lesion Size by CE-BMRI Scan</measure>
    <time_frame>Within 1 week of CE-BMRI scan</time_frame>
    <description>Average maximum lesion size when scanned using CE-BMRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Maximum Lesion Size by DE-CEDM</measure>
    <time_frame>Within 1 week of DE-CEDM scan</time_frame>
    <description>Average maximum lesion size when scanned using DE-CEDM</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Maximum Lesion Size by Histology Outcome</measure>
    <time_frame>Approximately 1 week; upon completion of histology report</time_frame>
    <description>Average maximum lesion size as described in histology report.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multi-reader Evaluation of Images</measure>
    <time_frame>This outcome did not occur due to premature study stop.</time_frame>
    <description>Multi-reader evaluation of images and comparison between CE-BMRI vs. DE-CEDM to determine which technology can more precisely measure cancer size as determined by pathological examination was planned. This was not conducted due to premature stop of the study.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>CE-BMRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will undergo bilateral CE-BMRI as per usual clinical practice within 30 days after the new breast cancer diagnosis. Subject will then undergo bilateral DE-CEDM examination within 8 weeks after the CE-BMRI exam.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CE-BMRI</intervention_name>
    <description>Contrast-enhanced breast imaging using Magnetic Resonance</description>
    <arm_group_label>CE-BMRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DE-CEDM</intervention_name>
    <description>Breast imaging using Dual-energy, contrast-enhanced digital mammography</description>
    <arm_group_label>CE-BMRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Woman 21 years of age or older

          -  The subject is able and willing to comply with study procedures and signed and dated
             informed consent is obtained.

          -  Newly diagnosed with Breast Cancer (DCIS or invasive) identified through core biopsy
             or fine-needle aspiration (FNA) within last 30 days.

          -  Will have or have had a bilateral CE-BMRI performed within 30 days AFTER the new
             breast cancer diagnosis.

        Exclusion Criteria:

          -  Woman who has already had a lumpectomy for the index lesion.

          -  Woman undergoing neoadjuvant chemotherapy treatment, hormone treatment or radiation
             therapy.

          -  Woman who is pregnant or who believe she may be pregnant.

          -  Woman who has breast implant.

          -  Woman who has a contraindication to the intravenous use of iodinated or
             gadolinium-chelated contrast agent (e.g., allergy to either agent or severely impaired
             renal function).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St-Jan Brugge AV</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Science Centre</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Goustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut fur Radiologie, Charite</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 18, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <results_first_submitted>February 27, 2019</results_first_submitted>
  <results_first_submitted_qc>March 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2019</results_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mammography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women 21 years of age or older, with newly diagnosed cancer identified through through core biopsy or fine-needle aspiration (FNA) within the last 30 days and with a bilateral CE-BMRI performed within 30 days of the new breast cancer diagnosis.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>CE-BMRI and DE-CEDM Examinations</title>
          <description>Subject will undergo bilateral CE-BMRI as per usual clinical practice within 30 days after the new breast cancer diagnosis. Subject will then undergo bilateral DE-CEDM examination within 8 weeks after the CE-BMRI exam.
CE-BMRI: Contrast-enhanced breast imaging using Magnetic Resonance
DE-CEDM: Breast imaging using Dual-energy, contrast-enhanced digital mammography</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="224">Subjects who met all Inclusion and none of the Exclusion criteria</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinuation of study</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not complete both imaging methods</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet all I/E after screening</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants enrolled in study.</population>
      <group_list>
        <group group_id="B1">
          <title>CE-BMRI and DE-CEDM Examinations</title>
          <description>Subject will undergo bilateral CE-BMRI as per usual clinical practice within 30 days after the new breast cancer diagnosis. Subject will then undergo bilateral DE-CEDM examination within 8 weeks after the CE-BMRI exam.
CE-BMRI: Contrast-enhanced breast imaging using Magnetic Resonance
DE-CEDM: Breast imaging using Dual-energy, contrast-enhanced digital mammography</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="224"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Subjects age 21 years or older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Completion of CE-BMRI and DE-CEDM</title>
        <description>Subjects have completed both CE-BMRI and DE-CEDM scan types</description>
        <time_frame>Approximately 8 weeks</time_frame>
        <population>Total number of participants enrolled in the study</population>
        <group_list>
          <group group_id="O1">
            <title>CE-BMRI and DE-CEDM Examinations</title>
            <description>Subject will undergo bilateral CE-BMRI as per usual clinical practice within 30 days after the new breast cancer diagnosis. Subject will then undergo bilateral DE-CEDM examination within 8 weeks after the CE-BMRI exam.
CE-BMRI: Contrast-enhanced breast imaging using Magnetic Resonance
DE-CEDM: Breast imaging using Dual-energy, contrast-enhanced digital mammography</description>
          </group>
        </group_list>
        <measure>
          <title>Completion of CE-BMRI and DE-CEDM</title>
          <description>Subjects have completed both CE-BMRI and DE-CEDM scan types</description>
          <population>Total number of participants enrolled in the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Subjects completing both scan types</title>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subjects did not complete both scan typess</title>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Maximum Lesion Size by CE-BMRI Scan</title>
        <description>Average maximum lesion size when scanned using CE-BMRI</description>
        <time_frame>Within 1 week of CE-BMRI scan</time_frame>
        <population>All subjects who completed both CE-BMRI and DE-CEDM examinations</population>
        <group_list>
          <group group_id="O1">
            <title>CE-BMRI and DE-CEDM Examinations</title>
            <description>Subject will undergo bilateral CE-BMRI as per usual clinical practice within 30 days after the new breast cancer diagnosis. Subject will then undergo bilateral DE-CEDM examination within 8 weeks after the CE-BMRI exam.
CE-BMRI: Contrast-enhanced breast imaging using Magnetic Resonance
DE-CEDM: Breast imaging using Dual-energy, contrast-enhanced digital mammography</description>
          </group>
        </group_list>
        <measure>
          <title>Average Maximum Lesion Size by CE-BMRI Scan</title>
          <description>Average maximum lesion size when scanned using CE-BMRI</description>
          <population>All subjects who completed both CE-BMRI and DE-CEDM examinations</population>
          <units>millimeters (mm)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" lower_limit="6.0" upper_limit="110.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Maximum Lesion Size by DE-CEDM</title>
        <description>Average maximum lesion size when scanned using DE-CEDM</description>
        <time_frame>Within 1 week of DE-CEDM scan</time_frame>
        <population>All subjects who completed both CE-BMRI and DE-CEDM examinations</population>
        <group_list>
          <group group_id="O1">
            <title>CE-BMRI and DE-CEDM Examinations</title>
            <description>Subject will undergo bilateral CE-BMRI as per usual clinical practice within 30 days after the new breast cancer diagnosis. Subject will then undergo bilateral DE-CEDM examination within 8 weeks after the CE-BMRI exam.
CE-BMRI: Contrast-enhanced breast imaging using Magnetic Resonance
DE-CEDM: Breast imaging using Dual-energy, contrast-enhanced digital mammography</description>
          </group>
        </group_list>
        <measure>
          <title>Average Maximum Lesion Size by DE-CEDM</title>
          <description>Average maximum lesion size when scanned using DE-CEDM</description>
          <population>All subjects who completed both CE-BMRI and DE-CEDM examinations</population>
          <units>millimeters (mm)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" lower_limit="5.0" upper_limit="150.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Maximum Lesion Size by Histology Outcome</title>
        <description>Average maximum lesion size as described in histology report.</description>
        <time_frame>Approximately 1 week; upon completion of histology report</time_frame>
        <population>Subjects who underwent CE-BMRI and DE-CEDM</population>
        <group_list>
          <group group_id="O1">
            <title>CE-BMRI and DE-CEDM Examinations</title>
            <description>Subject will undergo bilateral CE-BMRI as per usual clinical practice within 30 days after the new breast cancer diagnosis. Subject will then undergo bilateral DE-CEDM examination within 8 weeks after the CE-BMRI exam.
CE-BMRI: Contrast-enhanced breast imaging using Magnetic Resonance
DE-CEDM: Breast imaging using Dual-energy, contrast-enhanced digital mammography</description>
          </group>
        </group_list>
        <measure>
          <title>Average Maximum Lesion Size by Histology Outcome</title>
          <description>Average maximum lesion size as described in histology report.</description>
          <population>Subjects who underwent CE-BMRI and DE-CEDM</population>
          <units>millimeters (mm)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" lower_limit="4.0" upper_limit="169.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Multi-reader Evaluation of Images</title>
        <description>Multi-reader evaluation of images and comparison between CE-BMRI vs. DE-CEDM to determine which technology can more precisely measure cancer size as determined by pathological examination was planned. This was not conducted due to premature stop of the study.</description>
        <time_frame>This outcome did not occur due to premature study stop.</time_frame>
        <population>Study was prematurely stopped.</population>
        <group_list>
          <group group_id="O1">
            <title>CE-BMRI and DE-CEDM Examinations</title>
            <description>Subject will undergo bilateral CE-BMRI as per usual clinical practice within 30 days after the new breast cancer diagnosis. Subject will then undergo bilateral DE-CEDM examination within 8 weeks after the CE-BMRI exam.
CE-BMRI: Contrast-enhanced breast imaging using Magnetic Resonance
DE-CEDM: Breast imaging using Dual-energy, contrast-enhanced digital mammography</description>
          </group>
        </group_list>
        <measure>
          <title>Multi-reader Evaluation of Images</title>
          <description>Multi-reader evaluation of images and comparison between CE-BMRI vs. DE-CEDM to determine which technology can more precisely measure cancer size as determined by pathological examination was planned. This was not conducted due to premature stop of the study.</description>
          <population>Study was prematurely stopped.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of scan - approximately 1 hour</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CE-BMRI and DE-CEDM Examinations</title>
          <description>Subject will undergo bilateral CE-BMRI as per usual clinical practice within 30 days after the new breast cancer diagnosis. Subject will then undergo bilateral DE-CEDM examination within 8 weeks after the CE-BMRI exam.
CE-BMRI: Contrast-enhanced breast imaging using Magnetic Resonance
DE-CEDM: Breast imaging using Dual-energy, contrast-enhanced digital mammography</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>extravasation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to contrast media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jean-Paul Antonini</name_or_title>
      <organization>GE Healthcare</organization>
      <phone>+33 130709703</phone>
      <email>Jean-Paul.antonini@ge.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

